GB Sciences, Inc. (18C.SG)
Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
As of 08:22AM CEST. Market open.
| Previous Close | 0.0040 |
| Open | 0.0050 |
| Bid | 0.0040 x 0 |
| Ask | 0.0090 x 0 |
| Day's Range | 0.0050 - 0.0050 |
| 52 Week Range | 0.0040 - 0.0130 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 2.927M |
| Beta (5Y Monthly) | 0.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Gb Sciences’ Novel Parkinson’s Disease Medication is Featured on Worldwide Business with kathy ireland(R)
Tune in this Sunday, Dec. 17, at 5:30 p.m. ET on the Fox Business Network to learn about Gb Sciences' cannabinoid-based medicine for the treatment of Parkinson's disease.LAS VEGAS, NV / ACCESSWIRE / December 14, 2023 / Gb Sciences, Inc. (OTCQB:GBLX), ...
- ACCESSWIRE
Gb Sciences' First-in-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study at the University of Lethbridge
Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, has successfully completed a dose response study in rodents at the University of Lethbridge that supports Gb Sciences' cannabinoid-based therapy for Parkinson's disease. The study has established dose ranges and the corresponding times to onset and duration of action in a rodent model.
© 2024 Yahoo. All rights reserved.